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Abstract
Background  and  objective:  Sugammadex  is  the  ﬁrst  selective  relaxant  binding  agent.  When
compared  with  neostigmine,  following  sugammadex  administration  patients  wake  earlier  and
have shorter  recovery  times.  In  this  study,  we  hypothesized  that  fast  and  clear  awakening  in
patients  undergoing  general  anesthesia  has  positive  effects  on  cognitive  functions  in  the  early
period after  operation.
Methods:  Approved  by  the  local  ethical  committee,  128  patients  were  enrolled  in  this
randomized,  prospective,  controlled,  double-blind  study.  Patients  were  allocated  to  either  Sug-
ammadex  group  (Group  S)  or  the  Neostigmine  group  (Group  N).  The  primary  outcome  of  the  study
was early  postoperative  cognitive  recovery  as  measured  by  the  Montreal  Cognitive  Assessment
(MoCA)  and  Mini  Mental  State  Examination  (MMSE).  After  baseline  assessment  12--24  h  before
the operation.  After  the  operation,  when  the  Modiﬁed  Aldrete  Recovery  Score  was  ≥9  the  MMSE
and 1  h  later  the  MoCA  tests  were  repeated.
Results:  Although  there  was  a  reduction  in  MoCA  and  MMSE  scores  in  both  Group  S  and  Group  N
between preoperative  and  postoperative  scores,  there  was  no  statistically  signiﬁcant  difference
in the  slopes  (p  >  0.05).  The  time  to  reach  TOF  0.9  was  2.19  min  in  Group  S  and  6.47  min  in  Group
e  was  8.26  min  in  Group  S  and  16.93  min  in  Group  N  (p  <  0.0001).
at  the  surgical  procedure  and/or  accompanying  anesthetic  pro-
orary  or  permanent  regression  in  cognitive  function  in  the  earlyN (p  <  0.0001).  Recovery  tim
Conclusion:  We  showed  th
cedure may  cause  a  temp∗ Corresponding author.
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postoperative  period.  However,  better  cognitive  performance  could  not  be  proved  in  the  Sug-
ammadex  compared  to  the  Neostigmine.
© 2015  Sociedade  Brasileira  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.  This  is  an
open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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O  efeito  de  sugamadex  sobre  a  func¸ão  cognitiva  e  recuperac¸ão  no  pós-operatório
Resumo
Justiﬁcativa  e  objetivo:  Sugamadex  é  o  primeiro  agente  de  ligac¸ão  relaxante  seletivo.  Após
a administrac¸ão  de  sugamadex,  os  tempos  de  despertar  e  de  recuperac¸ão  dos  pacientes  são
menores, em  comparac¸ão  com  neostigmina.  Neste  estudo,  a  hipótese  foi  que  um  despertar
mais rápido  e  claro  dos  pacientes  submetidos  à  anestesia  geral  possui  efeitos  positivos  sobre  as
func¸ões cognitivas  no  pós-operatório  imediato.
Métodos:  Após  a  aprovac¸ão  do  Comitê  de  Ética  local,  128  pacientes  foram  incluídos  neste  estudo
prospectivo,  randômico,  controlado  e  duplo-cego.  Os  pacientes  foram  designados  para  o  grupo
sugamadex  (Grupo  S)  ou  grupo  neostigmina  (Grupo  N).  O  desfecho  primário  do  estudo  foi  a
recuperac¸ão cognitiva  no  pós-operatório  imediato,  de  acordo  com  a  mensurac¸ão  da  Avaliac¸ão
de Montreal  da  Func¸ão  Cognitiva  (MoCA)  e  com  o  Mini  Exame  do  Estado  Mental  (MMSE).  Após  a
avaliac¸ão inicial  12--24  h  antes  da  operac¸ão.  Após  a  operac¸ão,  quando  o  escore  de  Recuperac¸ão
de Aldrete  modiﬁcado  era  ≥  9,  o  teste  MMSE  e,  uma  hora  depois,  o  teste  MoCA  foram  repetidos.
Resultados:  Embora  tenha  havido  uma  reduc¸ão  nos  escores  de  MoCA  e  MMSE  tanto  no  Grupo
S quanto  no  Grupo  N,  entre  os  escores  pré-  e  pós-operatório,  não  houve  diferenc¸a  estatisti-
camente signiﬁcativa  nas  reduc¸ões  (p  >  0,05).  O  tempo  para  atingir  TOF  0.9  foi  de  2,19  min  no
Grupo S  e  de  6,47  min  no  Grupo  N  (p  <  0,0001).  O  tempo  de  recuperac¸ão  foi  de  8,26  min  no
Grupo S  e  de  16,93  min  no  Grupo  N  (p  <  0,0001)
Conclusão:  Mostramos  que  o  procedimento  cirúrgico  e/ou  procedimento  anestésico  de  acom-
panhamento  pode  causar  uma  regressão  temporária  ou  permanente  da  func¸ão  cognitiva  no
pós-operatório  imediato.  No  entanto,  um  desempenho  cognitivo  melhor  não  pode  ser  provado
no grupo  sugamadex  em  comparac¸ão  com  o  grupo  neostigmina.
© 2015  Sociedade  Brasileira  de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.  Este e´  um
artigo Open  Access  sob  uma  licenc¸a  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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were  between  18  and  60  years  of  age,  and  had  American
Society  of  Anesthesiologists  (ASA)  scores  of  I  or  II.Introduction
Patients  who  undergo  major  surgery  with  general  anesthe-
sia  may  experience  memory  impairment  and  regression  of
high-executive  functions  such  as  ordering,  planning,  and
organization  after  the  operation.1 This  intellectual  and
cognitive  worsening  is  known  as  postoperative  cognitive  dys-
function  (POCD).  POCD  often  creates  temporary  cognitive
impairment  but,  especially  in  older  patients,  it  may  take  the
form  of  permanent  decline.1 To  date,  controlled  studies  and
animal  models  have  not  established  diagnostic  criteria  for
POCD,  and  its  etiology  is  not  fully  understood.2--4 However,
animal  studies  have  provided  strong  evidence  that  expo-
sure  to  anesthetic  agents  may  cause  permanent  learning  and
memory  impairment.5--8
Sugammadex  (Bridion®,  Merck  Sharp  and  Dohme  (MSD),
Oss,  The  Netherlands)  is  a  rapid  and  selectively  effective
aminosteroid  agent  that  has  recently  entered  use.  Through
rocuronium  and  vecuronium  encapsulation,  it  causes  rapid
recovery  independent  of  the  time  of  administration.9--13
Compared  to  patients  given  neostigmine  to  recover,  patients
given  sugammadex  have  been  observed  to  recover  with  a
clearer  level  of  consciousness. aIn  this  study,  we  hypothesized  that  fast  and  clear  awak-
ning  in  patients  undergoing  general  anesthesia  has  positive
ffects  on  cognitive  functions  in  the  early  period  after
peration.  To  test  this  hypothesis,  postoperative  cognitive
unctions  of  patients  were  evaluated,  comparing  those  given
eostigmine  or  sugammadex  for  revival  after  general  anes-
hesia  with  rocuronium-based  neuromuscular  block.
ethod
his  randomized,  prospective,  controlled,  double-blind
tudy  was  approved  by  the  Bülent  Ecevit  University  Prac-
ice  and  Research  Hospital  Ethics  Committee  (2012/07-7).
he  study  included  patients  with  planned  operations  under
eneral  anesthesia  (abdominal  surgery;  upper  extremity
rthopedic  interventions;  gynecology;  plastic  surgery;  urol-
gy;  ear,  nose,  and  throat;  and  spinal  surgery  operations
asting  at  least  60  min)  who  could  read  and  write  Turkish,Exclusion  criteria  were  congestive  heart  failure,  renal
nd  hepatic  failure,  adrenal  failure,  hormonal  disorder,
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iabetes  mellitus  (DM),  neuropsychiatric  disease,  chronic
lcohol  or  drug  addiction,  Glasgow  Coma  Scale  (GCS)  <15,
istory  of  cardiopulmonary  arrest  or  stroke  in  the  previous
2  months,  history  of  previous  operation  under  general  anes-
hesia,  emergency  surgery,  and  postoperative  Mini-Mental
tate  Examination14 (MMSE)  score  <23  and  Montreal  Cogni-
ive  Assessment15 (MoCA)  score  <21.
After  receiving  informed  patient  consent,  the  sugam-
adex  (Group  S)  and  neostigmine  (Group  N)  groups  were
reated  using  the  closed-envelope  method.  To  evaluate  cog-
itive  functions,  the  MMSE  and  MoCA  tests  were  carried
ut  by  the  same  neurology  expert  blinded  to  the  patient’s
roup  assignment.  All  patients  were  visited  12--24  h  before
he  operation.  The  patients’  educational  level,  accompany-
ng  diseases,  and  demographic  information  were  recorded.
efore  the  operation  the  patients’  memory,  attentive  exec-
tive  functions,  and  motor  skills  were  evaluated  with  the
MSE  and  MoCA  tests  as  a  control  cognitive  evaluation
T0).  After  the  operation,  in  the  PACU,  when  the  Modiﬁed
ldrete  Recovery  Score16 (MAS)  was  ≥9  the  MMSE  and  1  h
ater  the  MoCA  tests  were  repeated  (T1).  Neither  group
as  given  premedication.  During  the  operation  mean  arte-
ial  pressure  (MAP),  heart  rate  (HR),  peripheral  oxygen
aturation  (SpO2),  bispectral  index  (BIS),  and  adductor  mus-
le  and  nasopharyngeal  temperature  were  monitored  and
ecorded.  For  neuromuscular  transmission  monitoring  a TOF-
ATCH® SX  (Organon  Teknika  B  V,  Netherlands)  device  was
sed.  The  temperature  of  the  operating  room  was  set  to
1--25 ◦C.  The  patients  were  covered,  and  the  skin  temper-
ture  of  the  thenar  region  was  monitored  to  ensure  it  did
ot  fall  below  32 ◦C.  All  patients  were  given  intravenous
IV)  fentanyl  (1  g/kg)  and  propofol  (2  mg/kg)  for  anesthesia
nduction.  When  BIS  values  were  40--60,  TOF  device  cali-
ration  was  completed  and  three  consecutive  single  twitch
ontrol  values  were  recorded.  Then,  IV  0.5  mg/kg  rocuro-
ium  was  administered  and  the  interval  until  TOF  values
eached  0  (TOF0)  was  recorded.  When  TOF0 was  reached  the
atients  were  intubated.  To  maintain  anesthesia  all  patients
ere  given  50:50  O2/N2O  and  2%  sevoﬂurane  titrated  to
aintain  BIS  values  between  40  and  60.  During  the  oper-
tion,  when  TOF  values  were  25%  (TOF25),  a  dose  of  one
uarter  of  the  initial  dose  of  rocuronium  was  administered.
t  the  end  of  the  operation,  when  TOF25 was  reached,  Group
 was  given  IV  2  mg/kg  sugammadex  and  Group  N  was  given
V  0.03  mg/kg  neostigmine  +  0.01  mg/kg  atropine.  Patients
ere  extubated  when  their  TOF  values  reached  90%  (TOF90).
he  interval  between  TOF25 and  TOF90 was  recorded  in  sec-
nds  (TOF25--90).  During  the  operation,  amounts  of  additional
edication  and  total  rocuronium  were  recorded.  After  skin
uturing  was  ﬁnished,  anesthetic  gases  were  stopped  in  both
roups.  This  time  was  recorded  as  the  end  of  anesthesia.
he  time  from  when  anesthetic  gases  were  stopped  until
AS  ≥  9  was  recorded  as  the  recovery  period.  After  the  oper-
tion,  patients  were  transferred  to  the  PACU.  All  patients
ere  given  IV  1 mg/kg  tramadol  after  the  skin  incision  was
nished  for  postoperative  pain  relief.  At  20,  40,  60,  and
20  min  post-operation,  visual  analog  scores17 (VAS)  were
ecorded.  When  VAS  >  4  a  non-steroidal  anti-inﬂammatory
nalgesic  agent  was  administered  and  recorded.
The  primary  outcome  of  the  study  was  early  postop-
rative  cognitive  recovery  as  measured  by  the  MoCA  and
MSE.  The  secondary  outcome  was  time  from  the  start  of
d
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GÖ.  Pis¸kin  et  al.
he  reversal  administration  to  the  recovery  of  a  ratio  of  0.9
n  patients  receiving  rocuronium  as  NMBA  during  general
nesthesia  for  a  surgical  procedure.
ower  analysis
o  test  the  signiﬁcance  of  differences  between  repeated
easures  in  dependent  groups  the  conventional  effect  size
equired  for  the  t  test  is  assumed  to  be  medium  (d  =  0.50),
o  for  the  study  to  have  80%  power  it  was  calculated  that
oth  groups  needed  a minimum  sample  size  of  128  (n  =  64).18
tatistical  analysis
tatistical  analyses  for  this  study  were  completed  using
he  SPSS  for  Windows  15.0  software  package.  Descriptive
tatistics  were  used  (mean,  median,  standard  deviation,
inimum  and  maximum  values)  to  evaluate  data.  Measure-
ent  values  are  given  as  means  and  standard  deviations.
ategorical  variables  (number  values)  are  given  as  numbers
nd  percentages.  The  chi-square  test  was  used  to  com-
are  categorical  variables.  The  Levene’s  test  was  used  to
valuate  the  homogeneity  within  groups  for  parametric  con-
itions.  If  the  results  of  the  homogeneity  tests  showed  that
arametric  conditions  were  met,  mixed  ANOVA  was  used
or  comparisons  between  groups;  if  parametric  conditions
ere  not  met,  the  Wilcoxon  signed-rank  test  was  used  to
ompare  measurement  values  before  and  after,  and  the
ann--Whitney  U  test  was  used  for  comparisons  of  indepen-
ent  groups.  Signiﬁcance  was  accepted  at  p  <  0.05.
esults
his  study  was  conducted  from  September  2012  to  July
013  with  128  patients.  Thirty-eight  patients  were  excluded
ecause  their  MMSE  and  MoCA  target  scores  were  low,  and
hree  were  excluded  because  they  could  not  be  extubated
t  the  end  of  the  operation.  Of  the  87  patients  included  in
he  study,  48.2%  (n  =  42)  were  in  Group  S and  51.8%  (n  =  45)
ere  in  Group  N.
The  demographic  characteristics  of  the  patients  are  pre-
ented  in  Table  1.  The  total  amount  of  rocuronium  consumed
as  67.02  ±  15.85  mg  in  Group  S  and  62.44  ±  11.65  mg  in
roup  N  (Table  1).  There  was  a statistically  signiﬁcant
ifference  in  average  age  between  the  groups  (p  <  0.05).
here  were  no  signiﬁcant  differences  between  the  groups  in
eight,  BMI,  duration  of  operation,  duration  of  anesthesia,
nd  total  amount  of  rocuronium  consumed  (p  >  0.05).
The  time  to  reach  TOF  0.9  was  2.19  min  in  Group  S and
.47  min  in  Group  N  (p  <  0.0001).  Recovery  time  was  8.26  min
n  Group  S  and  16.93  min  in  Group  N  (p  <  0.0001)  (Table  2).
The  MMSE  T0 and  T1 scores  in  Group  S  were  26.98  ±  1.957
nd  26.90  ±  1.936,  and  in  Group  N  were  27.00  ±  2.286  and
5.82  ±  2.724,  respectively.  The  MoCA  T0 and  T1 scores  in
roup  S  were  23.26  ±  1.988  and  23.17  ±  2.294  and  in  Group  N
ere  23.56  ±  2.482  and  23.04  ±  2.868,  respectively.  In  both
ests  the  T1 mean  was  lower  than  the  T0 mean.  Depen-
ent  groups  were  compared  with  the  t-test,  and  repeated
easurement  values  were  compared.  To  determine  the  dif-
erence  between  the  MMSE  and  MoCA  at  T0 and  T1,  the
eneral  Linear  Model  repeated  measurement  test  was  used.
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Table  1  Distribution  of  sociodemograﬁc  factors  and  operative  details  via  groups.
Group  S  (±SD)
(n  =  42)
Group  N  (±SD)
(n  =  45)
pa
Mean  age,  years  32.07  ±  11.50  37.38  ±  11.95  <0.05
Gender (F/M)  12/30  22/23  >0.05
Education years(<9  years/9--12  years/>12  years)  12/18/12  17/18/10  >0.05
Weight, kg  74.83  ±  14.93  75.33  ±  13.92  >0.05
BMI, kg/cm2 25.25  ±  4.08  26.70  ±  4.63  >0.05
ASA class  (I/II)  17/25  18/27  >0.05
Duration of  the  operation,  min  118.86  ±  42.94  115.49  ±  46.51  >0.05
Duration of  the  anesthesiology,  min 125.21  ±  38.91 124.18  ±  48.39 >0.05
Rocuronium, mg 67.02  ±  15.85 62.44  ±  11.65 >0.05
Tramadol, mg 74.83  ±  14.93 75.33  ±  13.92 >0.05
F, Female; M, Male; BMI, body mass index; ASA, American Society of Anesthesiologist score.
a Chi-square test (2 × n) and Independent sample t test.
Table  2  Time  to  recovery  of  TOF  ratio  to  0.9  (min)  and  tıme  to  recovery  of  Aldrete  ≥  9  (min).
Group  S  (±SD)  Group  N  (±SD)  pa
Time  to  recovery  of  TOF  ratio  to  0.9  2.19  ±  1.47  6.47  ±  1.92  <0.0001
Time to  recovery  of  Aldrete  ≥9  8.26  ±  5.02  16.93  ±  8.00  <0.0001
N
e
DTOF, train of four.
a Independent t test for groups.
The  test  results  are  illustrated  in  Fig.  1,  which  shows  that
although  the  T0 and  T1 MMSE  values  in  Group  S  were  reduced,
the  slope  of  the  reduction  did  not  show  a  statistically  signif-
icant  difference  (p  >  0.05).  In  Group  N,  although  there  was
a  statistically  signiﬁcant  fall  in  MMSE  values  from  T0 to  T1
(p  <  0.05)  there  was  no  statistically  signiﬁcant  difference
between  the  slope  values.  Fig.  2  indicates  that  although
there  was  a  reduction  in  MoCA  values  in  both  Groups  S  and
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Figure  1  MMSE  score  slopes  of  the  groups  from  T0 to  T1.
I
a from  T0 to  T1, there  was  no  statistically  signiﬁcant  differ-
nce  in  the  slopes  (p  >  0.05)  (Table  3;  Fig.  3).
iscussionn  this  study,  the  effects  of  sugammadex  on  recovery
nd  cognitive  functions  were  compared  with  those  of
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Figure  2  MoCA  score  slopes  of  the  groups  from  T0 to  T1.
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Table  3  MMSE  and  MoCA  scores  at  preoperative  and  post-
operative  period.
T0 (±SD)  T1 (±SD)  pa
Group  S
MMSE  26.98  ±  1.957  26.90  ±  1.936  >0.05
MoCA 23.26  ±  1.988  23.17  ±  2.294  >0.05
Group N
MMSE  27.00  ±  2.286  25.82  ±  2.724  <0.05
MoCA 23.56  ±  2.482  23.04  ±  2.868  >0.05
T0, preoperative; T1, postoperative.
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eostigmine.  Although  the  sugammadex  group  reached  TOF
.9  earlier  than  the  neostigmine  group  and  had  shorter
ecovery  times,  no  signiﬁcant  improvement  in  cognitive
ecovery  was  identiﬁed.
Surgical  procedures  and  accompanying  anesthetic  pro-
edures  may  cause  temporary  or  permanent  postoperative
egression  in  cognitive  functions;  this  situation  is  known
s  POCD.4 However,  whether  the  surgical  procedure
r  anesthesia  administration  causes  POCD  is  not  fully
nderstood.2,3,19,20 Many  randomized  controlled  studies  have
hown  that  the  incidence  of  POCD  increases  in  patients
ho  are  older  or  undergoing  cardiopulmonary  bypass  and
ower  extremity  orthopedic  operations.20 To  determine  the
ffect  of  sugammadex  and  neostigmine  on  cognitive  func-
ion,  this  study  excluded  patients  above  the  age  of  60  years
nd  those  undergoing  cardiac,  cranial,  and  lower  extrem-
ty  operations.  Independent  risk  factors  for  development
f  POCD  were  eliminated.  In  addition,  there  was  a  signif-
cant  difference  in  average  age  between  the  two  groups
Group  S:  32.07  ±  11.50  and  Group  N:  37.38  ±  11.95).  John-
on  et  al.21 found  that  the  incidence  of  POCD  was  very  low
n  middle-aged  individuals  and  determined  that  there  was
o  signiﬁcant  difference  in  POCD  between  patients  who  had
ndergone  an  operation  in  the  previous  3  months  and  healthy
olunteers.  Therefore,  we  believe  that  the  difference  in
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ge  between  the  two  groups  did  not  negatively  affect  the
ognitive  test  scores.
There  is  no  international  consensus  on  how  cognitive
unction  should  be  evaluated  after  an  operation.22 To  this
nd,  almost  30  tests  have  been  described,  but  their  advan-
ages  have  not  been  demonstrated.  The  MMSE  test  is
requently  used  to  evaluate  cognitive  function  after  anes-
hesia  because  it  takes  a shorter  time  to  administer,  and  has
een  found  to  be  more  useful  by  patients  and  physicians.
he  MoCA  test  has  become  popular  recently  and  is  used  fre-
uently  as  it  is  not  dependent  on  demographic  variables  such
s  age  and  education.23 Both  the  MMSE  and  MoCA  tests  have
igh  validity  and  reliability,  with  Turkish  validity  and  reli-
bility  studies  having  been  completed.23,24 Based  on  these
actors,  the  MMSE  and  MoCA  tests  were  used  to  evaluate
ognitive  function  in  this  study.
There  are  some  reservations  about  when  and  how  fre-
uently  cognitive  evaluation  tests  should  be  performed
fter  operations.2,3,20 Factors  that  may  negatively  affect
he  cognitive  evaluation  scores  are  pain  after  the  opera-
ion,  disrupted  sleep,  and  learning/memorizing  of  the  tests
ue  to  their  frequent  repetition.1 In  this  study,  to  prevent
he  effects  of  these  factors  all  patients  had  a  VAS  score
4  and  MAS  score  ≥9  before  postoperative  evaluation.  In
ddition,  to  prevent  memorizing  and  learning  of  the  eval-
ation  tests,  the  tests  were  only  conducted  once  after  the
peration.
It  is  not  known  exactly  when  brain  function  returns
fter  general  anesthesia.  Studies  have  shown  that  cogni-
ive  functions  are  affected  by  several  factors  after  surgical
rocedures  with  anesthesia.1--3,19 As  rapid  and  short-term
ffective  anesthetic  agents  are  metabolized  less  by  the
ody,  they  may  cause  less  cognitive  dysfunction.  Matthew
t  al.,8 in  a  study  of  921  patients  undergoing  major  non-
ardiac  surgery,  administered  to  one  group  a  standard
nesthetic  protocol  while  the  other  group  received  a  BIS-
uided  titrated  anesthetic  protocol.  The  BIS-guided  group
as  exposed  less  to  anesthetic  agents  and  was  determined
o  have  less  POCD  in  the  3  months  after  surgery.  This  study
sed  BIS  in  both  groups  to  reduce  exposure  to  anesthetics
nd  for  monitoring.
Sugammadex  has  entered  anesthetic  practice  in  recent
ears  and  is  used  to  reverse  the  neuromuscular  block  cre-
ted  by  rocuronium  and  vecuronium  in  a rapid  and  reliable
ashion.  When  compared  with  neostigmine,  following  sug-
mmadex  administration  patients  wake  earlier  and  have
horter  recovery  times.11--13 In  comparative  studies  with
eostigmine,  the  time  required  for  TOF  to  reach  0.9  was  con-
iderably  shorter  for  patients  given  sugammadex.11,13,25,26 In
 randomized,  controlled  study  by  Koc¸  et  al.,25 when  the
OF  ratio  of  patients  with  neuromuscular  block  provided  by
ocuronium  reached  2,  sugammadex  2  mg/kg  or  neostigmine
0  g/kg  +  atropine  20  g/kg  were  administered  for  decu-
arization.  The  time  to  reach  TOF  0.9  was  2.31  min  in  the
ugammadex  group  and  9.48  min  in  the  neostigmine  group.
he  same  study  found  that  the  extubation  time  was  6.64  min
n  the  sugammadex  group  and  12.99  min  in  the  neostig-
ine  group.  Similarly,  Pongrácz  et  al.26 compared  the  timeo  reach  TOF  1.0  in  patients  given  different  amounts  of
ugammadex  (0.5,  1,  or  2  mg/kg)  or  0.005  mg/kg  neostig-
ine.  Patients  given  2  mg/kg  sugammadex  reached  TOF  1.0
n  1.8  min  while  those  given  0.05  mg/kg  neostigmine  reached
R1
1
1
1
1
1
1
1
1
1
2Sugammadex  and  cognitive  function  
TOF  1.0  in  8.5  min.  In  our  study,  the  time  to  reach  TOF  0.9
for  patients  given  sugammadex  was  2.19  min,  and  the  recov-
ery  time  was  8.26  min,  while  for  patients  given  neostigmine
these  times  were  6.47  and  16.93  min.  The  patients  given  sug-
ammadex  woke  and  recovered  earlier  than  did  those  given
neostigmine.
Many  studies  of  the  effects  of  fast  emergence  and  recov-
ery  from  anesthesia  on  postoperative  cognitive  function
have  been  conducted.  Bronco  et  al.27 compared  the  effects
of  a  rapid-start  and  recovery  inhalation  agent,  xenon,  with
another  inhalation  agent,  sevoﬂurane,  in  terms  of  post-
operative  recovery  and  cognitive  function.  Patients  in  the
xenon  group  had  an  earlier  emergence  time  and  better  cog-
nitive  recovery.  Coburn  et  al.28 compared  the  effects  of
xenon  with  desﬂurane  on  postoperative  cognitive  function
in  elderly  patients;  the  eye-opening  and  extubation  peri-
ods  were  shorter  in  the  xenon  group;  however,  the  authors
stated  that  the  effects  on  cognitive  function  were  simi-
lar  to  those  of  desﬂurane.  Similarly,  Rasmussen  et  al.29
determined  that  the  effects  on  cognitive  function  of  the
fast-acting  inhalation  agent  xenon  and  fast-acting  intra-
venous  propofol  were  similar  in  elderly  patients.  In  our
study,  to  evaluate  the  cognitive  function  in  both  groups,
MMSE  and  MoCA  tests  were  administered  at  T0 and  T1.
Although  there  was  a  numerical  reduction  in  MMSE  and  MoCA
scores  at  T1 compared  to  T0,  there  was  no  statistically  sig-
niﬁcant  difference  in  the  reduction  slopes.  Studies  have
shown  that  the  surgical  procedure  and/or  accompanying
anesthetic  procedure  may  cause  a  temporary  or  permanent
regression  in  cognitive  function  in  the  early  postoperative
period.  However,  better  cognitive  performance  could  not
be  proved  in  the  sugammadex  patients  compared  to  the
neostigmine  patients.  No  prior  studies  comparing  the  cogni-
tive  performance  of  sugammadex  and  neostigmine  patients
were  found.
Calculating  the  sample  size  for  an  80%  strength  required
each  group  to  include  64  patients,  for  a  total  of  128;  how-
ever,  exclusion  criteria  meant  that  the  study  was  completed
with  87  patients.  Limitations  in  terms  of  the  project  duration
meant  that  backup  groups  were  not  included.  This  was  the
most  important  limitation  of  the  study.  In  addition,  post-
operative  cognitive  evaluation  was  completed  only  during
the  early  period.  As  a  result,  the  effects  of  sugammadex  on
cognitive  function  were  compared  only  in  the  early  period.
Another  limitation  of  the  study  was  that  low  doses  of  sug-
ammadex  (2  mg/kg)  were  used.  As  a  result,  the  effect  of
high-dose  (16  mg/kg)  sugammadex  on  POCD  development  is
unknown.
In  conclusion,  evaluating  cognitive  function  after  an
operation  is  complicated;  the  many  independent  risk
factors  and  multitude  of  evaluation  tests  add  to  the  difﬁ-
culty.
Sugammadex  is  a  very  new  agent.  Further  studies  that
include  more  detailed  statistical  analysis,  different  doses  of
sugammadex,  and  larger  sample  sizes  are  needed  to  fully
understand  the  effects  of  this  agent  on  cognitive  function  in
the  late  postoperative  period.Conﬂicts of interest
The  authors  declare  no  conﬂicts  of  interest.
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